OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma By Ogkologos - August 4, 2025 602 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PANOVA-3 study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR A New Era of Early Cancer Detection With Blood Test May... September 11, 2022 Artificial Intelligence Brings Pancreatic Cancer Screening One Step Closer to Reality... July 2, 2020 Fine Needle Aspiration Biopsy: How to Prepare and What to Expect October 7, 2021 Clinical Trials in Molecular Testing for Early-Stage Lung Cancer: IMpower010, ADAURA,... June 15, 2022 Load more HOT NEWS Excellence in cancer research nursing: Celebrating innovation during tough times FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced... Persistent Poverty Linked to Increased Risk of Dying from Cancer Woman Battles Breast Cancer While Pregnant, Delivers Healthy Baby Boy
